M. Oliveira

发表

Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial

I. Kozarewa, K. Fenwick, G. Schiavon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

Mafalda Oliveira, S. López-Tarruella Cobo, J. Gavilá Gregori, 2019, Clinical and Translational Oncology.

SEOM clinical guidelines in metastatic breast cancer 2015

M. Martín, S. Morales, I. Álvarez, 2015, Clinical and Translational Oncology.

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

L. Carey, A. Bardia, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

S. Loi, N. Lin, G. Curigliano, 2019, The New England journal of medicine.

Edinburgh Research Explorer Tucatinib, Trastuzumab and Capecitabine for HER2+ Metastatic Breast Cancer

S. Loi, N. Lin, C. Anders, 2019 .

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of the axilla in early breast cancer patients in the genomic era.

S. Di Cosimo, I. Rubio, J. Balmaña, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

K. Tamura, C. Corcoran, G. Schiavon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Sudden death during adjuvant trastuzumab therapy of breast cancer.

N. Gil, J. Passos-Coelho, M. Nave, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

P. Nuciforo, A. Prat, P. Villagrasa, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

P. Nuciforo, A. Prat, P. Villagrasa, 2021, npj Precision Oncology.

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.

P. Nuciforo, D. Patt, L. de la Peña, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

B. González-Farré, T. Pascual, M. Espinosa-Bravo, 2022, Annals of Oncology.

202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer

B. González-Farré, T. Pascual, J. Guerra, 2022, Annals of Oncology.

214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

A. Bardia, F. Marmé, M. Motwani, 2022, Annals of Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

B. Cantos, N. Martínez, E. Ciruelos, 2022, Annals of Oncology.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .

130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype

P. Villagrasa, X. Gonzalez-Farre, J. Cortés, 2021 .

124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.

Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.

B. González-Farré, D. Sellami, J. M. Ferrero-Cafiero, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial

A. Prat, J. M. Ferrero-Cafiero, T. Pascual, 2023, ESMO Open.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

M. Berger, J. Reis-Filho, L. Norton, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.